Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tina Cascone

Showing results (31-40 of 123) with videos related to

Pageof 13
Sort By:
Cancer Treatment Reviews|February 20, 2025
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the targetGiannis Mountzios, Stephanie P L Saw, Lizza Hendriks, et al.
Cancer Research|March 15, 2014
Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacyReza Mehran, Monique Nilsson, Mehrdad Khajavi, et al.
Journal of Cellular Physiology|May 12, 2006
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinasesMaria Pia Morelli, Tina Cascone, Teresa Troiani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLCSonia A Patel, Matthew H Herynk, Tina Cascone, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2024
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline MutationsKelsey Pan, Jennifer Owens, Yasir Elamin, et al.
The Journal of Biological Chemistry|September 5, 2021
Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancersJayanthi P Gudikote, Tina Cascone, Alissa Poteete, et al.
Clinical Lung Cancer|April 14, 2020
Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant ChemotherapyAnnikka Weissferdt, Apar Pataer, Ara A Vaporciyan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLCSonia A Patel, Monique B Nilsson, Yan Yang, et al.
The Annals of Thoracic Surgery|December 9, 2017
Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung CancerTina Cascone, Kathryn A Gold, Stephen G Swisher, et al.
The Annals of Thoracic Surgery|September 25, 2019
Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung CancerKyle G Mitchell, Marcelo V Negrao, Edwin R Parra, et al.
Pageof 13

Showing results (31-40 of 123) with videos related to

Sort By:
Pageof 13
Cancer Treatment Reviews|February 20, 2025
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the targetGiannis Mountzios, Stephanie P L Saw, Lizza Hendriks, et al.
Cancer Research|March 15, 2014
Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacyReza Mehran, Monique Nilsson, Mehrdad Khajavi, et al.
Journal of Cellular Physiology|May 12, 2006
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinasesMaria Pia Morelli, Tina Cascone, Teresa Troiani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLCSonia A Patel, Matthew H Herynk, Tina Cascone, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2024
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline MutationsKelsey Pan, Jennifer Owens, Yasir Elamin, et al.
The Journal of Biological Chemistry|September 5, 2021
Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancersJayanthi P Gudikote, Tina Cascone, Alissa Poteete, et al.
Clinical Lung Cancer|April 14, 2020
Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant ChemotherapyAnnikka Weissferdt, Apar Pataer, Ara A Vaporciyan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLCSonia A Patel, Monique B Nilsson, Yan Yang, et al.
The Annals of Thoracic Surgery|December 9, 2017
Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung CancerTina Cascone, Kathryn A Gold, Stephen G Swisher, et al.
The Annals of Thoracic Surgery|September 25, 2019
Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung CancerKyle G Mitchell, Marcelo V Negrao, Edwin R Parra, et al.
Pageof 13